Abstract
There is an increased influx of activated eosinophils to the intestinal mucosa in active ulcerative colitis, and an increased release of eosinophil-derived proteins, such as ECP, has also been observed. These findings indicate that eosinophils may contribute to tissue damage and intestinal inflammation in this disease. The relative importance of different chemotactic factors and the impact of steroid treatment on their effect in active ulcerative colitis are not known. We measured the eosinophil chemotactic activity in perfusion fluids from 11 patients with ulcerative colitis before and after steroid treatment and from 7 control patients. The effect of neutralizing antibodies to IL-5 and -8, RANTES, eotaxin, MCP-3, TNF-α, GM-CSF was investigated. The chemotactic activity was higher in perfusion fluids from patients than from controls (P = 0.0043). Anti-IL-5 (P = 0.005) and -TNF-α (P = 0.017) inhibited the activity in perfusion fluids obtained before treatment. Steroid treatment prevented the effect of all antibodies but had no significant effect on the chemotactic activity. The chemotactic activity correlated with the levels of eosinophil granule proteins in the perfusion fluids. In conclusion, in ulcerative colitis, eosinophils are attracted to the intestinal tissue by chemotactic factors, of which IL-5 and TNF-α may be the most prominent steroid-sensitive ones. The steroid-insensitive chemotactic activities remain unidentified.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Makiyama K, Zea-Iriarte W, Tsuji X: Activation of eosinopils in the pathophysiology of ulcerative colitis. J Gastroenterol 30:64–69, 1995
Raab Y, Fredens K, Gerdin B, Hällgren R: Eosinophil activation in ulcerative colitis. Studies on mucosal release and localization of eosinophil granule constituents. Dig Dis Sci 43:1061–1070, 1998
Bischoff SC, Meier PN, Trautwein C, Cetin Y, Maschek H, Stolte M, Gebel M, Manns MP: Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathol 28:1–13, 1996
Dubucquoi S, Janin A, Klein O, Desreumaux P, Quandalle P, Cortot A, Capron M, Colombel J-F: Activated eosinophils and interleukin-5 expression in early recurrence of Crohn' disease. Gut 67:242–246, 1995
Carlson M, Raab Y, Peterson C, Hällgren R, Venge P: Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am J Gastroenterol 94:1876–1883, 1999
Bischoff SC: Mucosal allergy: Role of mast cells and eosinophil granulocytes in the gut. Baill Clin Gastroenterol 10:443–459, 1996
Koizumi M, King N, Lobb R, Benjamin C, Podolsky DK: Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 103:840–847, 1992
Venge J, Lampinen M, Håkansson L, Rak S, Venge P: Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung. J Allergy Clin Immunol 97:1110–1115, 1996
Lampinen M, Rak S, Venge P: The role of interleukin-5, interleukin-8 and RANTES in the chemotactic attraction of eosinophils to the allergic lung. Clin Exp Allergy 29:314–322, 1999
Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD: Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nature Med 2:449–456, 1996
Noso N, Proost P, Van Damme J, Schröder J-M: Human monocyte chemotactic proteins-2 and 3 (MCP-2 and MCP-3) attract human eosinophils and desensitize the chemotactic resonses towards RANTES. Biochem Biophys Res Commun 200:1470–1476, 1994
Bischoff SC, Lorentz A, Schwengberg S, Weier G, Raab R, Manns MP: Mast cells are an important cellular source of tumour necrosis factor alfa in human intestinal tissue. Gut 44:643–652, 1999
Wedemeyer J, Lorentz A, Göke M, Flemming P, Dahinden CA, Manns MP, Bischoff SC: Enhanced production of monocyte chemotactic protein-3 in inflammatory bowel disease mucosa. Gut 44:629–635, 1999
Mazzucchelli L, Hauser C, Z'graggen K, Wagner HE, Heiss MW, Laissue JA, Mrowietz U, Mueller C: Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease. J Pathol 178:201–206, 1996
Frieri M: Corticosteroid effects on cytokines and chemokines. Allergy Asthma Proc 20:147–159, 1999
Raab Y, Hällgren R; Knutson L, Krog M, Gerdin B: A technique for segmental rectal and colonic perfusion in humans. Am J Gastroenterol 87:1453–1459, 1992
Hansel TT, De Vries IJM, Iff T, Rihs S, Wandzilak M, Betz S, Blaser K, Walke C: An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods 145:105–110, 1991
Falk W, Goodwin RH Jr, Leonard EJ: A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration. J Immunol Methods 33:239–247, 1980
Wilkinson PC: Principles of the measurement of leukocyte chemotaxis using Boyden' method. Chemotaxis and inflammation. London, Churchill Livingston, 1974; pp 33–53
Håkansson L, Venge P: Priming of eosinophil and neutrophil migratory responses by interleukin-3 and interleukin-5. APMIS 102:1–7, 1994
Schweizer RC, Welmers BAC, Raaijmakers JAM, Zanen P, Lammers J-WJ, Koenderman L: RANTES-and interleukin-8-induced responses in normal human eosinophils: Effects of priming with interleukin-5. Blood 83:3697–3704, 1994
Nagata M, Fukuda T, Numao T, Makino S, Dohi Y: Tumor necrosis alpha induces migration of human eosinophils. Arerugi 42:549–555, 1993
Bittleman DB, Erger R, Casale TB: Cytokines induce selective granulocyte chemotactic responses. Inflamm Res 45:89–95, 1999
Macari DMT, Teixeira MM, Ansari T, Jeffery PK, Hellewell PG: Priming and induction of eosinophil trafficking in guineapig cutaneous inflammation by tumour necrosis factor α. Br J Pharmacol 125:1228–1235, 1998
Reinecker H-C, Steffen M, Witthoeft T, Pflueger F, Schreiber S, Mac Dermott RP, Raedler A: Enhanced secretion of tumour necrosis factor-α IL-6 and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn' disease. Clin Exp Immunol 94:174–181, 1993
Baert F, D'Haens G, Peeters M, Hiele MI, Schaible T, Shealy D, Geboes K, Rutgeerts P: Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the in-flammation in Crohn' ileocolitis. Gastroenterology 116:22–28, 1999
Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM: Treatment of ulcerative colitis with an engineered human anti-TNF alpha antibody CDP571. Aliment Pharmacol Ther 11:1031–1035, 1999
Koenderman L, van der Bruggen T, Schweizer RC, Warringa RAJ, Coffer P, Caldenhoven E, Lammers J-WJ, Raaijmakers JAM: Eosinophil priming by cytokines: From cellular signal to in vivo modulation. Eur Respir J 6:119–125, 1998
Mould AW, Matthaei KI, Young IG, Foster PS: Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice. J Clin Invest 99:1064–1071, 1997
Schleimer RP: Glucocorticoids: Their mechanism of action and use in allergic disease. In Allergy Principles and Practice. E Middleton, CE Reed, EF Ellis (eds). St. Louis, Mosby, 1993; pp 893–925
Schleimer RP, Beck L, Schweibert L: Inhibition of inflammatory cell recruitment by glucocorticoides: cytokines as primary targets. In Inhaled Glucocorticoids in Asthma. Mechanisms and Clinical Actions. RP Schleimer, WW Busse, P O'Byrne (eds). New York, Marcel Dekker, 1997, pp 203–238
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lampinen, M., Carlson, M., Sangfelt, P. et al. IL-5 and TNF-α Participate in Recruitment of Eosinophils to Intestinal Mucosa in Ulcerative Colitis. Dig Dis Sci 46, 2004–2009 (2001). https://doi.org/10.1023/A:1010659803912
Issue Date:
DOI: https://doi.org/10.1023/A:1010659803912